AFYX

Overview
AFYX is an innovative niche developer of pharmaceuticals aiming at securing better treatments of diseases with unmet medical At AFYX - Reversed Innovation is our core value.
As a leader in the biopharmaceutical industry, reversed innovation aligns with our broader theme, as we take an existing product or technology and use it to address a new or previously overlooked or unconsidered medical problem or condition. For more information please click here.

Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and secured successful IPOs of 3 companies in the BioPharma Industry (OXiGENE, Inc; Genmab A/S and Y-mAbs Therapeutics, Inc.)

OUR HISTORY
AFYX is based on the merger of three great and innovative companies bringing significant synergies together – the companies were:

Lionheart, a company focused on treatment of chronic and intermittent cluster headache. A dramatic a severely debilitating disease with limited treatment options available – We have patent protection for the use of ketamine as nasal administration in this indication.

AFYX Therapeutics A/S, a company based on development of a proprietary patented patch technology that sticks to wet surfaces and delivers pharmaceutical products locally where the patch is applied. Our two first projects focus on inflammatory diseases in the oral cavity – oral lichen planus – also a significant unmet medical need and precancerous stages of head and neck cancer in the mouth where we aim to develop a chemotherapy containing patch.

Inphena A/S, a company that already has commercial activities in several countries and develop repurposed existing pharmaceutical substances for new indications.

We look forward to welcoming AFYX at our different conferences, committees, and socials. Learn more about them on their website https://afyxtx.com/.